Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
MWN-AI** Summary
Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) announced a significant advancement in its development of therapies for neurodevelopmental disorders, specifically with the identification of two pediatric-friendly liquid formulations of its lead compound, MB-204. This breakthrough comes with support from the National Research Council of Canada via the Industrial Research Assistance Program (NRC IRAP), focusing on creating a small-volume oral liquid formulation suitable for children and adolescents who struggle with standard pill forms, including those reliant on feeding tubes.
The formulations were designed to meet critical criteria including the use of well-accepted excipients, high drug concentration in low volumes, simple manufacturing processes, stability at room temperature, and high oral bioavailability. Dr. Mark Williams, CSO of Marvel, expressed optimism about the two formulations, noting their success in achieving 79% and 91% oral bioavailability in pre-clinical studies, which suggests promising drug exposure levels for patients in upcoming Phase I trials.
This development marks a crucial step for Marvel as it transitions to a clinically focused entity, expanding accessibility to MB-204 among its target populations. The findings are not only expected to enhance regulatory engagement but also to strengthen the company's intellectual property portfolio concerning innovative drug delivery methods.
Marvel Biosciences, through its subsidiary Marvel Biotechnology Inc., is committed to developing treatments for neurological diseases, utilizing MB-204’s potential benefits, which derive from its fluorinated derivative formulation of Istradefylline. The company is exploring MB-204's efficacy in conditions such as autism, depression, Alzheimer’s disease, and rare syndromes like Rett and Fragile X, aspiring to provide effective therapeutic options where few exist.
MWN-AI** Analysis
Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) has made significant strides in developing pediatric-friendly liquid formulations of its lead compound, MB-204, for neurodevelopmental disorders. This advancement not only caters to children and adolescents, who often struggle with traditional pill forms, but also positions Marvel strategically within a niche market that continues to grow due to rising incidence rates of issues like autism and ADHD.
The successful identification of two high bioavailability formulations (79% and 91%) adds a substantial competitive edge for Marvel. By achieving effective blood concentration levels, the Company enhances the likelihood of positive outcomes in upcoming Phase I trials. These developments foster confidence in investors and stakeholders regarding both clinical viability and potential market success.
From a market perspective, this pivotal transition towards clinical readiness represents a substantial value inflection point. Investors should closely monitor Marvel’s scheduled regulatory engagement and forthcoming clinical results, as positive outcomes will likely lead to increased stock value. Furthermore, the secured NRC IRAP grant underscores institutional confidence in Marvel's capabilities, which may attract additional investments.
As Marvel advances in its development pathway, the expected additional formulation filings will likely bolster its intellectual property portfolio, providing further competitive advantages against peers in the biotech space. Additionally, the growing pipeline targeting rare disorders indicates a broader market potential and enhances Marvel’s attractiveness to long-term investors.
Investors should consider entering or increasing their stake in Marvel, particularly before the Phase I trial results are released. However, it's critical to remain aware of the inherent risks associated with biotech investments, particularly with companies at the pre-commercialization stage. Diversification remains a key strategy as the company navigates the complexities of clinical trials and regulatory requirements. Keeping abreast of new developments will be essential for stakeholders in this fast-evolving space.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.
This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess:
- Well accepted clinic ready excipients
- A high concentration/low volume dosing solution
- A simple, economic manufacturing process
- Long term stability at room temperature
- High oral bioavailability
“We believe we have identified two very attractive liquid-based formulations that fit all of our criteria”, commented Dr. Mark Williams, CSO of Marvel Biosciences. “Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. We wish to thank the NRC for their support of this project as it helps Marvel in its transition from a pre-clinical to a clinically focused company.”
The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.
About Marvel Biosciences Corp.
Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson’s drug and the only adenosine A2A receptor blocker currently on the market.
Research shows that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer’s disease. Marvel is also exploring MB-204’s potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments.
Website: www.marvelbiotechnology.com | Twitter/X | LinkedIn
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is de?ned in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and o?cers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identi?ed by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could di?er materially from those anticipated in such statements. Important factors that could cause actual results to di?er materially from the expectations of the Company and include other risks detailed from time to time in the ?lings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to di?er materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may di?er materially from those anticipated. Forward-looking statements contained in this news release are expressly quali?ed by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
Contact Information: Marvel Biosciences Corp.J. Roderick (Rod) Matheson, Chief Executive OfficerEmail: rod@marvelbiosciences.comDr. Mark Williams, President and Chief Science OfficerEmail: mark@marvelbiosciences.comTel: 403 770 2469
FAQ**
What specific pre-clinical results led Marvel Biosciences Corp. (MBCOF) to gain confidence in the efficacy of the MB-204 liquid formulations for treating pediatric patients with neurodevelopmental disorders?
How does the identification of the two lead liquid formulations for MB-204 position Marvel Biosciences Corp. (MBCOF) in terms of regulatory engagement and clinical trial readiness?
Given the potential of MB-204 in treating disorders like autism and Alzheimer’s, what strategies does Marvel Biosciences Corp. (MBCOF) have to strengthen its intellectual property portfolio around this compound?
What are the anticipated next steps for Marvel Biosciences Corp. (MBCOF) as it transitions from pre-clinical research to a clinically focused company following the development of MB-204?
**MWN-AI FAQ is based on asking OpenAI questions about Marvel Biosciences Corp. (TSXVC: MRVL:CC).
NASDAQ: MRVL:CC
MRVL:CC Trading
0.0% G/L:
$0.105 Last:
21,320 Volume:
$0.105 Open:
MRVL:CC Latest News
Wed, Jun 03, 2026 as of 4:00 pm ET
